FOXO4-DRI peptide, forkhead box O4 senescence inhibitor · Evidence-based safety and harm-reduction overview.
| Also known as | FOXO4-DRI peptide, forkhead box O4 senescence inhibitor |
| Category | Peptide |
| cell_penetrating | True |
| amino_acid_count | 14 |
| target | FOXO4-p53 interaction |
| US legal status | Not FDA-approved for human use. Investigational drug candidate for senescence and age-related diseases. Available for research purposes only. Not a dietary supplement or pharmaceutical product for general use. |
A cell-penetrating peptide (14 amino acids) designed to disrupt the interaction between FOXO4 and p53 proteins, thereby preventing cellular senescence and enabling senescent cell clearance. Targets aging at the cellular level via senolytic mechanisms.
FOXO4-DRI is a cell-penetrating peptide that inhibits FOXO4-p53 interaction. This prevents p53-mediated activation of senescence pathways, allowing immune clearance of senescent cells.
Discovered in 2017 by Dutch researchers at Erasmus University; showed remarkable anti-aging effects in mice. No commercial development in humans; remains experimental.
Preclinical mouse studies show FOXO4-DRI reduces senescent cell burden and improves multiple aging-related outcomes, including kidney function and muscle mass. No human clinical trials have been completed. Mechanism is sound in animal models, but translation to humans is unproven. Safety profile in humans is entirely unknown.
Mouse studies used 10-20 mg/kg; human-equivalent dosing unknown. No human dosing protocols established or tested.
This is general research/context information, not medical advice or a recommended protocol.
FOXO4-DRI stacking with other senolytic compounds or anti-aging agents is entirely theoretical; no human safety data.
If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.
Compare testing optionsNo. FOXO4-DRI is purely investigational with no approved human clinical trials. It is available for basic research only.
Senescent cells are aged or damaged cells that stop dividing and accumulate with age. They secrete inflammatory molecules contributing to aging. Clearing them theoretically may slow aging, but human evidence is absent.
Not in approved clinical trials. Some individuals may have obtained it through research channels, but adverse effects and efficacy in humans are completely unknown.
As a cell-penetrating peptide, it would require injection (systemic or local). Oral administration would not work due to peptide digestion.
No. FOXO4-DRI is not sold as a consumer product or pharmaceutical. It is available for laboratory research only in select institutions.
Medical & legal disclaimer. This site is for informational and harm-reduction purposes only. It is not medical advice and is not a substitute for a licensed healthcare professional. The compounds discussed are largely not approved by the FDA for human use and many are sold strictly as research chemicals 'not for human consumption.' Nothing here is an endorsement to purchase, possess, or use any substance. Laws vary by jurisdiction. Always consult a qualified physician and follow the law where you live.
Some links on this page may be affiliate links. If you buy through them we may earn a commission at no extra cost to you. This never changes the safety information we publish.